Stockreport
Regeneron Pharmaceuticals Suffers Worst Month in Two Years After Legal Setback [Yahoo! Finance]
Last amgen inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations: investors.amgen.com
Most Read from Bloomberg The stock is down about 12% in September through Thursday's close, making it the third-worst performer in the S&P 500 Index. The shares rose in early trading Friday on news that the company received approval in the US for a separate drug. They're still up about 21% in 2024. The shares had a rough start to the week. The big blow came Monday after a court ruling raised the possibility of Amgen Inc. launching a copycat version — known as a biosimilar — of Eylea as a federal judge in West Virginia denied Regeneron's motion for a preliminary injunction against Amgen's drug, Pavblu. The decision “creates uncertainty about prospects for the US Eylea franchise,” according to David Risinger, a Leerink Partners analyst who downgraded the stock this week to a market perform rating from outperform. Risinger said he had previously expected that Regeneron, which is based in Tarrytown, New York, would be able to settle with all copycat challengers for them to enter
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | AMGN | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
AMGN alerts
AMGN alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
AMGN alerts
High impacting Amgen Inc. news events
Weekly update
A roundup of the hottest topics
AMGN
NEWS
NEWS
- Amgen Inc. (NASDAQ: AMGN) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating and a $405.00 price target on the stock.[MarketBeat]
- AMGN Stock Falls Despite Upbeat Data on Immunology Drugs: Here's Why [Yahoo! Finance][Yahoo! Finance]
- Amgen Inc. (NASDAQ: AMGN) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $362.00 price target on the stock.[MarketBeat]
- Amgen Inc. (NASDAQ: AMGN) had its "underperform" rating re-affirmed by analysts at Robert W. Baird. They now have a $215.00 price target on the stock.[MarketBeat]
- TEPEZZA® (TEPROTUMUMAB) RECEIVES APPROVAL IN JAPAN FOR THE TREATMENT OF ACTIVE THYROID EYE DISEASE[PR Newswire]
- More
AMGN
SEC Filings
SEC Filings
- 8/13/24 - Form 4
- 8/13/24 - Form 4
- 8/13/24 - Form 4
- AMGN's page on the SEC website
- More